Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Purchases $54,500.00 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan bought 50,000 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was bought at an average cost of $1.09 per share, with a total value of $54,500.00. Following the transaction, the chief executive officer now owns 260,808 shares in the company, valued at $284,280.72. This trade represents a 23.72 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.00 on Monday. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $3.79. The company’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.54. The stock has a market capitalization of $65.50 million, a PE ratio of -0.93 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Regulus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGLS. Renaissance Technologies LLC boosted its position in shares of Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares during the period. SG Americas Securities LLC bought a new position in Regulus Therapeutics in the 3rd quarter worth $33,000. Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter worth $26,000. Tyche Wealth Partners LLC raised its holdings in Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares during the period. Finally, Victory Capital Management Inc. lifted its position in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after acquiring an additional 37,480 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.